Projects per year
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma.
Roberts, S., Lewis, P., George, J., Zekry, A., Tse, E., McLachlan, S., Eastgate, M., Ananda, S. S. & O'Beirne, J.
24/09/19 → 30/09/23
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis.
Burgell, R. & Hogg, J.
9/09/19 → 31/12/24
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma who are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2).
17/05/19 → 31/05/23
An Open-Label Study to Assess The Efficacy and Safety of LM011 In Subjects Diagnosed With Non-Alcoholic Steatohepatitis (NASH).
16/04/19 → 31/12/19
Comparison of Regional Transit Measurement for the Atmo Capsule with those of a Gold Standard (Smart Pill)
13/03/19 → 1/06/20
The impact of day-time and night-time endurance exercise on gastrointestinal integrity, functional responses, symptoms, and systemic endotoxin and cytokine profiles - A laboratory controlled mechanistic exploration of circadian variation influences in ultra-endurance athletes.
4/02/19 → 31/12/19
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1).
Roberts, S. & Lewis, P.
24/01/19 → 30/04/23
A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge.
Brown, G. & Secomb, R.
5/11/18 → 31/12/19
Open Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 +/- ribavirin (RBV) in the treatment of Hepatitis C G1 and 4, in patients either eligible for liver transplant (HCC) or curative therapy or non-eligible for curative therapy but clinically stable disease post local resection, embolization or ablative therapy: HATCHeT Study - HepATocellular Cancer Hcv Therapy Study.
Kemp, W. & Mitchell, J.
7/08/18 → 7/08/23
FODMAP: Changing therapeutic paradigms for intestinal health: Diet as a therapeutic strategy in Gastroenterology.
1/01/18 → 31/12/22
1/09/17 → 31/08/20